Latest News in the pharma Industry
Research & Development
Allergan expands leading R&D NASH Program with Novartis Clinical Collaboration
18 Apr 2017
Collaboration focused on Phase 2II clinical trial to evaluate use of Allergan's Cenicriviroc and Novartis' lead FXR agonist to treat NASH.
Read more
FDA issues complete response letter for baricitinib
16 Apr 2017
Additional clinical data are needed to determine the most appropriate doses.
Read more
BMS to license anti-eTau and anti-myostatic compounds
16 Apr 2017
Two separate agreements with Biogen and Roche.
Read more
Regen BioPharma sees success in Its pre-clinical small molecule optimization program for NR2F6
12 Apr 2017
The company's small molecule drug program is aimed at treating cancer and autoimmune diseases .
Read more
BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumours
12 Apr 2017
Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.
Read more
Lhasa and Optibrium enter research and product development collaboration
11 Apr 2017
Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling.
Read more
Phase III study shows Genentech’s Alecensa was superior to crizotinib in a specific type of lung cancer
10 Apr 2017
Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment.
Read more
New technology can detect tiny ovarian tumours
10 Apr 2017
“Synthetic biomarkers” could be used to diagnose ovarian cancer months earlier than now possible.
Read more
Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD
9 Apr 2017
Botox is currently being studied as a potential treatment option for adult patients with moderate to severe MDD.
Read more
Merck receives CRL from the FDA for TECOS study with sitagliptin
7 Apr 2017
CRL relates to Merck's sNDA for Januvia, Janumet and Janumet XR.
Read more
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
6 Apr 2017
ECF843 is a new therapeutic approach and potential first-in-class Rx treatment in dry-eye.
Read more
Kite presents promising preclinical data from KITE-585, a fully human anti-BCMA CAR T-cell product candidate
5 Apr 2017
Phase I clinical study of KITE-585 in patients with multiple myeloma planned for 2017.
Read more